Cited by 10Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCerebrospinal fluid and hydrocephalus

Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer’s disease

Open access
Lim, Bryant, Fowler, Christopher, Li, Qiao-Xin, Rowe, Christopher, Dhiman, Kunal, Gupta, Veer Bala, Masters, Colin L., Doecke, James D. +3 more·2020·Neuroscience Letters

Abstract

Multifactorial pathological processes of Alzheimer's disease (AD) begin decades prior to clinical onset. Early identification of patients at risk of developing AD using biomarkers reflecting various aspects of pathogenesis is necessary for prevention and early intervention. Cortical β-amyloid (Aβ) burden assessed by positron emission tomography (PET) or cerebrospinal fluid (CSF) levels of Aβ42 are validated biomarkers for early identification. Recently, alterations in levels of neuronal proteins, neuronal pentraxin receptor (NPTXR) and neurofilament light (NfL), in the CSF have emerged as promising AD biomarkers. However, their association with Aβ deposition is not well understood. In this pilot study, we evaluate whether CSF NfL and NPTXR are associated with PET-Aβ imaging and core CSF biomarkers (Aβ42, T-tau, and P-tau). CSF samples were collected from a sub-cohort of participants from the Australian Imaging Biomarkers and Lifestyle study of aging (AIBL) and categorized as either PET-Aβ positive (n = 15) or negative (n = 15). NPTXR was significantly lower in PET-Aβ positive than negative individuals (p = 0.04), and correlated with Aβ42 (rho = 0.69, p < 0.0001), T-tau (rho = 0.45, p = 0.01), and P-tau (rho = 0.51, p = 0.004). However, CSF NfL was not significantly different between PET-Aβ positive and negative individuals and did not correlate with any of the core CSF biomarkers. Similar associations of NPTXR and the core CSF biomarkers persisted in the cognitively normal individuals. Together, NPTXR concentration in CSF may be more sensitive NfL to identify AD risk during the preclinical stage, warranting further investigation into its contribution to AD pathogenesis.

Integrity signals

Registry

Crossref · 10.1016/j.neulet.2020.135078

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lim, B., Fowler, C., Li, Q.-X., Rowe, C., Dhiman, K., Gupta, V. B., Masters, C. L., Doecke, J. D., Martins, R. N., Collins, S., & Diamandis, E. P.
Affiliations
  • University of Toronto (CA)
  • The University of Melbourne (AU)
  • Edith Cowan University (AU)
  • Commonwealth Scientific and Industrial Research Organisation (AU)
  • Mount Sinai Hospital (CA)
Corresponding author
Diamandis, Eleftherios P.
Venue
Neuroscience Letters
Publisher
Elsevier BV
Published
2020-07
Volume
731
Pages
135078
ISSN
0304-3940 (ISSN-L)
OpenAlex
W3028203785
Cited by
10
References
45
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 1
FWCI
0.91
Type
journal article
Language
en
Open access
Locations
  • Neuroscience Letters (publishedVersion)
  • PubMed (publishedVersion)
  • Research Online (Edith Cowan University) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
Keywords
Alzheimer's disease, neurofilament light chain, cerebrospinal fluid biomarkers, amyloid-beta 42, tau protein, preclinical Alzheimer's disease, early detection of Alzheimer's disease, cognitively normal older adults
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Peptide Fragments, Receptors, Cell Surface, Biomarkers, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review